SG11201408262XA - Temperature stable vaccine formulations - Google Patents
Temperature stable vaccine formulationsInfo
- Publication number
- SG11201408262XA SG11201408262XA SG11201408262XA SG11201408262XA SG11201408262XA SG 11201408262X A SG11201408262X A SG 11201408262XA SG 11201408262X A SG11201408262X A SG 11201408262XA SG 11201408262X A SG11201408262X A SG 11201408262XA SG 11201408262X A SG11201408262X A SG 11201408262XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- maryland
- gaithersburg
- formulations
- pct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/07—Bacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261664062P | 2012-06-25 | 2012-06-25 | |
| US201361801385P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/047712 WO2014004578A1 (en) | 2012-06-25 | 2013-06-25 | Temperature stable vaccine formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408262XA true SG11201408262XA (en) | 2015-01-29 |
Family
ID=49783811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408262XA SG11201408262XA (en) | 2012-06-25 | 2013-06-25 | Temperature stable vaccine formulations |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150335752A1 (ko) |
| EP (1) | EP2863898A4 (ko) |
| JP (1) | JP2015525748A (ko) |
| KR (1) | KR20150034170A (ko) |
| CN (1) | CN104470506A (ko) |
| AU (1) | AU2013280480B2 (ko) |
| CA (1) | CA2877130A1 (ko) |
| HK (1) | HK1207312A1 (ko) |
| IL (1) | IL236380A0 (ko) |
| IN (1) | IN2015MN00038A (ko) |
| RU (1) | RU2014151424A (ko) |
| SG (1) | SG11201408262XA (ko) |
| WO (1) | WO2014004578A1 (ko) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3086780A4 (en) * | 2013-12-27 | 2017-08-09 | Emergent Product Development Gaithersburg Inc. | Temperature stable vaccine formulations |
| KR102411781B1 (ko) * | 2013-12-31 | 2022-06-22 | 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) | 단일 바이알 백신 제형 |
| US20170007690A1 (en) * | 2015-07-07 | 2017-01-12 | Nanobio Corporation | Methods and compositions for the stabilization of anthrax recombinant protective antigen |
| JP2018521129A (ja) * | 2015-07-07 | 2018-08-02 | ナノビオ コーポレイションＮａｎｏｂｉｏ Ｃｏｒｐｏｒａｔｉｏｎ | タンパク質の安定化のための方法および組成物 |
| US11173197B2 (en) | 2015-07-07 | 2021-11-16 | Bluewillow Biologics, Inc. | Methods and compositions for nanoemulsion vaccine formulations |
| WO2018050870A1 (en) | 2016-09-16 | 2018-03-22 | Leukocare Ag | A novel method for stabilization of a biopharmaceutical drug product during processing |
| US11510871B2 (en) | 2016-09-16 | 2022-11-29 | Leukocare Ag | Method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation |
| KR101744900B1 (ko) | 2017-01-20 | 2017-06-08 | 주식회사 대웅 | 보툴리눔 독소를 포함하는 안정한 액상 조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE235919T1 (de) * | 1994-06-02 | 2003-04-15 | Elan Drug Delivery Ltd | Methode zum verhindern der aggregation von proteinen/peptiden bei rehydratation oder auftauen |
| US7201912B2 (en) * | 2002-04-12 | 2007-04-10 | Emergent Biodefense Operation Lansing Inc. | Recombinant immunogenic compositions and methods for protecting against lethal infections from Bacillus anthracis |
| US9283260B2 (en) * | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
| CN100556400C (zh) * | 2006-07-20 | 2009-11-04 | 上海交通大学 | 载有活性疫苗或抗体的多糖玻璃体微粒的制备方法 |
| JP2010502747A (ja) * | 2006-09-08 | 2010-01-28 | ベクトン・ディキンソン・アンド・カンパニー | ミョウバン吸着ワクチンの安定粉末製剤 |
| US8444991B2 (en) * | 2007-03-22 | 2013-05-21 | The Regents Of The University Of Colorado, A Body Corporate | Method of preparing an immunologically-active adjuvant-bound dried vaccine composition |
| US8778359B2 (en) * | 2008-07-30 | 2014-07-15 | Emergent Biosolutions Inc. | Stable anthrax vaccine formulations |
| US20110212127A1 (en) * | 2008-09-24 | 2011-09-01 | Stabilitech Ltd. | Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine |
| CA2750321A1 (en) * | 2009-01-22 | 2010-07-29 | Pharmathene, Inc. | Stable vaccine compositions and methods of use |
-
2013
- 2013-06-25 RU RU2014151424A patent/RU2014151424A/ru not_active Application Discontinuation
- 2013-06-25 EP EP13809706.8A patent/EP2863898A4/en not_active Withdrawn
- 2013-06-25 AU AU2013280480A patent/AU2013280480B2/en not_active Ceased
- 2013-06-25 US US14/410,942 patent/US20150335752A1/en not_active Abandoned
- 2013-06-25 CA CA2877130A patent/CA2877130A1/en not_active Abandoned
- 2013-06-25 IN IN38MUN2015 patent/IN2015MN00038A/en unknown
- 2013-06-25 SG SG11201408262XA patent/SG11201408262XA/en unknown
- 2013-06-25 WO PCT/US2013/047712 patent/WO2014004578A1/en active Application Filing
- 2013-06-25 JP JP2015520412A patent/JP2015525748A/ja not_active Withdrawn
- 2013-06-25 KR KR20157000755A patent/KR20150034170A/ko not_active Application Discontinuation
- 2013-06-25 CN CN201380037918.7A patent/CN104470506A/zh active Pending
-
2014
- 2014-12-21 IL IL236380A patent/IL236380A0/en unknown
-
2015
- 2015-08-19 HK HK15108032.6A patent/HK1207312A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IN2015MN00038A (ko) | 2015-10-16 |
| CN104470506A (zh) | 2015-03-25 |
| AU2013280480A1 (en) | 2015-01-22 |
| RU2014151424A (ru) | 2016-08-20 |
| HK1207312A1 (en) | 2016-01-29 |
| JP2015525748A (ja) | 2015-09-07 |
| IL236380A0 (en) | 2015-02-26 |
| US20150335752A1 (en) | 2015-11-26 |
| EP2863898A1 (en) | 2015-04-29 |
| EP2863898A4 (en) | 2016-04-27 |
| KR20150034170A (ko) | 2015-04-02 |
| CA2877130A1 (en) | 2014-01-03 |
| AU2013280480B2 (en) | 2018-03-15 |
| WO2014004578A1 (en) | 2014-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408262XA (en) | Temperature stable vaccine formulations | |
| SG11201908391XA (en) | Methods for modulating an immune response | |
| SG11201808552XA (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
| SG11201903514VA (en) | Novel cd47 monoclonal antibodies and uses thereof | |
| SG11201906412SA (en) | Pyridine compounds as allosteric shp2 inhibitors | |
| SG11201807660QA (en) | Cyclic di-nucleotide compounds and methods of use | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201804729RA (en) | Methods and compositions for treating a serpinc1-associated disorder | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201804411TA (en) | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof | |
| SG11201408174UA (en) | Antibody formulation | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201804647TA (en) | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201407397WA (en) | Formulations and methods for vaginal delivery of antiprogestins | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201406987UA (en) | Glucokinase activator compositions for the treatment of diabetes | |
| SG11201810549TA (en) | Hiv vaccine formulation | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201902988UA (en) | Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate |